Last updated on July 2018

Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer

Brief description of study

BVAC-C is immunotherapeutic vaccine using B-Cell and Monocytes as antigen presenting cell. This study is Open-label, dose-escalation, multiple dosing study to evaluate the safety, tolerability, immune response and pre efficacy of BVAC-C in patients with multiple metastatic progressive or recurrent HPV type 16 or 18 positive cervical cancer after failure to standard care. 9~18 patients will be enrolled

Clinical Study Identifier: NCT02866006

Contact Investigators or Research Sites near you

Start Over

C H Choi, PH.D

Samsung Medical Center
Seoul, Korea, Republic of
  Connect »